A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions
Status:
Completed
Trial end date:
2001-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin
Tablets by Purepac Pharmaceutical Co. with that of 800 mg NEURONTIN® Tablets by Parke-Davis
following a single oral dose (1 x 800 mg) in healthy adult volunteers under fasting
conditions.